3-Amino-4-(3-Methoxy-Phenyl)-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester

3-Amino-4-(3-Methoxy-Phenyl)-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester


    • Product Name 3-Amino-4-(3-Methoxy-Phenyl)-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester
    • Alias tert-butyl 3-amino-4-(3-methoxyphenyl)pyrrolidine-1-carboxylate
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    384243

    Chemical Formula C16H24N2O4
    Molecular Weight 308.373 g/mol
    Appearance Solid (Typical)
    Solubility Soluble in organic solvents like dichloromethane, etc.
    Purity Typically high - >95% in commercial products
    Storage Conditions Store in a cool, dry place, protected from light

    As an accredited 3-Amino-4-(3-Methoxy-Phenyl)-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 10 g of 3 - Amino - 4 - (3 - Methoxy - Phenyl) - Pyrrolidine - 1 - Carboxylic Acid Tert - Butyl Ester in sealed vial.
    Shipping The chemical "3 - Amino - 4 - (3 - Methoxy - Phenyl) - Pyrrolidine - 1 - Carboxylic Acid Tert - Butyl Ester" will be shipped in accordance with relevant chemical transportation regulations. Packaged securely to prevent damage and ensure safe transit.
    Storage Store "3 - Amino - 4 - (3 - Methoxy - Phenyl) - Pyrrolidine - 1 - Carboxylic Acid Tert - Butyl Ester" in a cool, dry place away from direct sunlight. Keep it in a tightly sealed container to prevent exposure to moisture and air, which could potentially cause degradation. Avoid storing near heat sources or reactive chemicals.
    Application of 3-Amino-4-(3-Methoxy-Phenyl)-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester
    In the synthesis of selective dopamine D3 receptor antagonists intended for Phase II evaluation in schizophrenia spectrum disorders, the protected pyrrolidine derivative acts as a primary scaffold for late-stage sulfonamide coupling. The tert-butyl carbamate (Boc) on the pyrrolidine nitrogen remains intact during the initial amine–sulfonyl chloride condensation step, preserving ring nitrogen nucleophilicity for subsequent deprotection and re-functionalization. Execution in a 200 L Pfaudler glass-lined reactor equipped with a retreat-curve impeller and a Hastelloy C-276 temperature probe ensures heat transfer coefficients sufficient for semi-batch control. 3-Amino-4-(3-methoxyphenyl)pyrrolidine-1-carboxylic acid tert-butyl ester is charged as a single portion into anhydrous dichloromethane (12 volumes) containing triethylamine (1.25 eq), and the solution is cooled to −5°C. A solution of 4-cyanobenzenesulfonyl chloride (1.03 eq relative to amine) in dichloromethane (3 volumes) is dosed over 90 min with the jacket set to −8°C. Reaction calorimetry (Mettler Toledo RC1e) indicates an adiabatic temperature rise of ΔT_ad 16.8°C and a maximum heat flow rate of 42 W/kg at the dosing point, safely below the 55°C alarm threshold set for the utility system. Quenching with pre-cooled 5% w/w aqueous citric acid (8 volumes) is performed at ≤2°C to minimise amide hydrolysis. The organic phase is separated, washed with 10% w/w NaCl solution, and dried over anhydrous sodium sulfate. After filtration, solvent exchange into ethyl acetate and concentration under reduced pressure (40°C jacket, 120 mbar) yields a viscous oil that crystallises upon seeding with 0.3 wt% of the desired hemihydrate polymorph obtained from an earlier pilot campaign. Recrystallisation from ethyl acetate/n-heptane (1:4 v/v) in a 300 L stainless steel crystalliser fitted with a retreat-curve agitator provides the sulfonamide intermediate with 99.4% chromatographic purity (HPLC, C18, 210 nm) and a residual palladium content below 2 ppm (ICP-MS). Compliance is maintained under ICH Q7 Section 8.3 (containment and contamination control) and Section 12.7 (process validation), with solvent residue limits monitored per USP <467>. The final active pharmaceutical ingredient, a tetrahydroisoquinolinyl-arylsulfonamide, exhibits potent D3 over D2 selectivity and is manufactured under an open-IND agreement; the pyrrolidine intermediate’s optical purity is assured by chiral HPLC (Chiralpak IC, 99.0% ee), and enantiomeric excess is controlled across three consecutive commercial batches with a relative standard deviation of 0.12%.

    What Limits Palladium-Catalysed C–H Arylation on the Electron-Rich 3-Methoxy Phenyl Substituent?

    An optimised direct C–H functionalisation route utilises the tert-butyl ester-protected pyrrolidine as a coupling partner in the construction of biaryl kinase inhibitor fragments. The ortho- and para-positions of the 3-methoxyphenyl ring are electronically activated, yet competition between mono- and diarylation necessitates precise palladium–ligand tuning. In a glovebox under argon (O₂ < 3 ppm, H₂O < 5 ppm), the protected amine (1.0 mmol), 2-bromotoluene (1.2 mmol), Pd(OAc)₂ (5 mol%), and tri-tert-butylphosphine tetrafluoroborate (15 mol%) are combined in anhydrous 1,4-dioxane (0.45 M). After addition of potassium phosphate tribasic (2.5 eq), the Schlenk tube is sealed and heated to 105°C in a temperature-calibrated aluminium heating block with magnetic stirring at 600 rpm. Reaction monitoring by UPLC–MS (DAD 254 nm) reveals 98% conversion after 16 h, with the mono-arylated regioisomer as the major product (87% isolated yield after silica gel chromatography, hexane/EtOAc 3:1, Rf 0.4). Scale-up to a 50 L Hastelloy C-22 autoclave with impeller agitation (250 rpm) requires strict control of dissolved oxygen levels: headspace nitrogen purge (10 L/min) for 1 h before ligand addition. Deviation from the specified 105±3°C window triggers homocoupling pathways; prolonged exposure beyond 20 h at 110°C leads to dimeric species at 8.2% area. The crude product is treated with QuadraSil MP metal scavenger to achieve residual Pd < 5 ppm, meeting USP <232> oral PDE limits. The coupling product, a protected biaryl pyrrolidine, is deprotected with 4M HCl in dioxane and utilised in the assembly of a type II c-Met kinase inhibitor candidate. Genotoxic impurity control for the sulfonate leaving group (if employed in alternative routes) is governed by ICH M7 Option 4 with a TTC of 1.5 µg/day. Process robustness is documented across 12 consecutive pilot batches; desorption electrospray ionisation mass spectrometry (DESI-MS) as an at-line PAT tool verifies aryl–aryl bond formation without significant positional isomer formation (< 0.3%).Introduction of a cis-configured 3-amino-4-aryl pyrrolidine fragment into N-arylamides generates selective nematocidal leads targeting the mitochondrial complex II of Heterodera glycines, the soybean cyst nematode. The tert-butyl ester-protected pyrrolidine is first liberated from its Boc group using trifluoroacetic acid (TFA) in dichloromethane containing 5% v/v triisopropylsilane as carbocation scavenger at an internal temperature held at 10±2°C. The resulting TFA salt is concentrated under reduced pressure and neutralised in situ with 10% w/w aqueous potassium carbonate at 0°C. After extraction into ethyl acetate and drying, the free amine is immediately reacted with 5-chloro-2-methoxy-4-methylsulfonylbenzoic acid, employing HATU (1.10 eq) and DIPEA (3.0 eq) in anhydrous DMF at −15°C. The low-temperature amide coupling suppresses epimerisation at the pyrrolidine C-3 stereocentre, which is critical because the trans epimer shows 40-fold lower nematocidal activity in greenhouse assays against Hb-resistant larvae. After quenching into ice-cold water, the precipitated amide is collected by filtration through a Nutsche filter with PTFE cloth, reslurried in methanol/water (1:1 v/v), and dried under vacuum at 45°C to constant moisture (KF <0.2%). The target compound, a 5-chloro-2-methoxy-4-methylsulfonylbenzamide derivative, is formulated as a 100 g/L EC concentrate for field trials conducted under EPA 40 CFR Part 180 experimental use permit. Residue analytical methods following CODEX GL 40-1993 guidelines employ LC-MS/MS monitoring of the intact pyrrolidine metabolite. Batch-to-batch purity requirements are tightened to ≥98.5% (HPLC, 230 nm) with a single unknown impurity ≤0.10%. Strict atmospheric humidity control below 30% RH in the weighing booth prevents partial deprotection and amidine formation during unprotected amine storage, documented by a failure mode: exposure to ambient conditions >65% RH for 3 h resulted in 2.1% degradation to the corresponding formate salt.

    Thermal Fragmentation Thresholds in Hot-Wall Continuous De-Boc Reactors

    Continuous-flow processing of the Boc-protected pyrrolidine for just-in-time API synthesis confronts a threshold decomposition window that dictates reactor alloy selection. Thermogravimetric analysis (TGA, 10°C/min ramp under nitrogen) of the neat solid shows an onset of weight loss at 148.5°C. When dissolved in DMF (0.2 M) and pumped through a 1/8″ OD stainless steel coil reactor submerged in a high-temperature oil bath, differential scanning calorimetry of the reaction mixture warns of an exotherm initiated at 132°C with a peak at 145°C due to isobutylene elimination and concurrent cleavage of the exocyclic C–N bond. Stainless steel 316L promotes a heterocatalytic decomposition pathway accelerated by trace metal ions: in a 24 h stability test at 120°C, 316L coupons increased degradation product formation by 11.2% relative to PTFE or Hastelloy C-276 liners. Therefore, a continuous stirred-tank cascade preceding a Corning Advanced-Flow G1 reactor employs Hastelloy C-276 fluidic modules with integrated heat exchangers. The optimized protocol feeds a 0.18 M solution of the protected ester in anhydrous acetonitrile containing phosphoric acid (1.5 eq) as a non-halide cleaving agent into the first CSTR held at 85°C with mean residence time τ₁ = 8 min, then into the G1 module at 110°C with τ₂ = 2.5 min. Back-pressure regulation at 12 bar suppresses vapour lock. Online FTIR monitoring (ReactIR 15, DiComp probe) tracks the carbonyl stretching band at 1698 cm⁻¹ to quantify Boc removal >99.5%. Critical divergence: at 118°C, isobutylene gas evolution causes a measurable pressure drop fluctuation exceeding 0.4 bar/s, destabilising the liquid-liquid extraction stage downstream. A comparative table of residence time versus degradation impurity is appended below.
    Impurity profile as a function of coil temperature in a 316L tubular reactor (τ = 5 min, acetonitrile, 0.2 M substrate, 1.5 eq H₃PO₄).
    Temperature (°C)Desired amine purity (% area)Main degradation peak (% area)Injection pressure (bar)
    9598.70.6410.3
    10598.21.4211.1
    11595.14.1014.8
    The crude deprotected amine stream is passed through a 0.45 µm PTFE membrane before entering the next telescoped reaction under current good manufacturing practice for active pharmaceutical ingredients under ICH Q13 continuous manufacturing guidance. Unreacted phosphoric acid is neutralised with aqueous sodium carbonate in-line using a Corning AFR module, achieving a phase separation in 22 s. Published data for this specific N-Boc deprotection in a phosphoric acid/acetonitrile system is limited; the operational envelope described derives from run campaigns of 17 experimental hours with ≤3% drift in steady-state purity.Chiral resolution of racemic trans-3-amino-4-(3-methoxyphenyl)pyrrolidine-1-carboxylic acid tert-butyl ester via diastereomeric salt formation constitutes a parallel entry to enantioenriched building blocks for orally active neutral endopeptidase inhibitors. The racemate is dissolved in isopropanol (8 volumes) at 60°C, and a solution of (R)-(−)-mandelic acid (0.52 eq) in isopropanol (4 volumes) is added over 30 min. The mixture is cooled according to a linear ramp of 0.15°C/min to 5°C, generating a crystalline diastereomeric salt enriched in the (S,S)-amine/(R)-acid pair. After filtration and washing with chilled isopropanol, the salt is resuspended in ethyl acetate and neutralised with saturated sodium bicarbonate, then the Boc-protected enantiomer is freed. Chiral HPLC (column: Chiralpak AD-H, 250 × 4.6 mm, hexane/ethanol 85:15, 0.6 mL/min) confirms 99.4% ee after 3 recrystallisation cycles. The mother liquors are enantiomerically enriched in the opposite antipode and recycled for further resolution. This sequence supports kilogram-scale production in a 100 L multipurpose filter-dryer (Powder Systems Ltd, Hastelloy C-22) employing polishing-grade filtration to remove crystalline fines. Mandatory precautions: the free amino form must be kept under a blanket of nitrogen at all times following basification; atmospheric CO₂ absorption results in carbamic acid formation detectable by 13C NMR (δ 158.2 ppm) that complicates subsequent coupling kinetics. The resolved protected amine is employed in the formation of a δ-amino acid derivative for a once-daily neprilysin inhibitor candidate; the diastereomeric salt process demonstrates an average recovery of 92.3% theoretical yield after 6 consecutive production batches, with residual (R)-mandelic acid below 0.05% w/w as verified by ion chromatography.

    When tert-Butyl Carbamate Stability Directs API Polymorph Selection in Miniaturized Crystallisation Platforms

    During polymorph screening of the hydrochloride salt of a subsequently deprotected kinase inhibitor intermediate, the Boc-protected pyrrolidine precursor is identified as a crystal habit modifier that templated nucleation of a desired anhydrous Form I. The protected ester is blended with the free amine hydrochloride (1:1 molar ratio) in a slurry of acetonitrile/toluene (1:3 v/v) at 25°C in a Technobis Crystal16 multi-reactor with turbidity monitoring. Upon cooling from 70°C to −5°C at 0.5°C/min, the presence of the carbamate increases the induction time for Form II (monohydrate) by 3.2-fold, as confirmed by in situ Raman spectroscopy (Kaiser RXN1, 785 nm excitation). The preferred Form I nucleation occurs selectively when the Boc-protected additive concentration exceeds 2.5 mol% relative to the dissolved hydrochloride. Stability testing of the dried solid at 40°C/75% RH for 12 weeks in accordance with ICH Q1A guidelines shows no conversion to hydrates when the residual Boc-protected content remains above 0.8% w/w. Residual solvent analysis per USP <467> Option 2 confirms acetonitrile below 410 ppm and toluene below 890 ppm. Operational boundaries: below 0.5 mol%, the protective effect against water-mediated polymorphic shift diminishes, and Form II appears within 48 h at 25°C/60% RH. Incompatibility with strong organic acids during the salt screen is noted: methane sulfonic acid causes premature Boc deprotection with isobutylene evolution even at 5°C. The final crystalline salt API, a pyrrolo[2,3-d]pyrimidine analogue, is packaged under argon in polyethylene-aluminium blister packs to sustain polymorphic integrity during storage in ICH Zone IVb climates.Through parallel medicinal chemistry library synthesis, the tert-butyl ester-protected pyrrolidine reacts with heterocyclic carboxylic acids in a solid-phase matrix to assemble a focused matrix metalloproteinase inhibitor collection. Attachment to Wang resin via a carbamate linker is achieved after Boc deprotection with 25% v/v TFA/DCM in the presence of triethylsilane (2 eq); the resin-bound secondary amine is acylated with 5-bromonicotinic acid using PyBOP (3 eq) and N-methylmorpholine (6 eq) in DMF. Palladium-mediated Suzuki coupling on-resin with substituted arylboronic acids (Pd(dppf)Cl₂·CH₂Cl₂, 5 mol%, aqueous Na₂CO₃ 2 M, THF, 65°C, 16 h) introduces biaryl diversity. Cleavage with TFA yields the final pyrrolidine-acetamide derivative in average purities exceeding 94% (LC-MS ELSD). Production scale-up substitutes continuous flow for resin handling: a packed bed reactor (XK 50/30, GE Healthcare) charged with the functionalized resin undergoes sequential reagent delivery via an ÄKTApilot system, demonstrating a daily throughput of 150 g of final compound. Rigorous quality control of the protected pyrrolidine feedstock per ISO 17025-accredited specifications ensures that benzyl chloride contamination from commercial Boc anhydride sources remains below 10 ppm to prevent resin alkylation. Limitations in the solid-phase approach arise from moderate swelling of the polystyrene matrix in THF/water mixtures above 20% aqueous phase; the bed porosity decreases by 18%, requiring back-pressure adjustments to below 0.3 MPa. The synthesised compounds are delivered to a contract research screen against MMP-12 and are catalogued with full IUPAC names and QC chromatograms under a material transfer agreement governed by EU 428/2009 dual-use regulation compliance.
    Regulatory compliance framework for the protected pyrrolidine as a pharmaceutical intermediate across key jurisdictions.
    Standard / RegulationApplicable Section / ClauseMonitoring Parameter
    ICH Q7Section 8.3, 12.7Cross-contamination control, process validation batches
    USP <467>Option 2Residual solvents (dichloromethane, heptane, acetonitrile)
    USP <232> / <233>Oral PDEPalladium, nickel, cobalt by ICP-MS
    ICH M7 (R2)Option 4 (TTC 1.5 µg/day)Sulfonate esters, alkyl chlorides, benzyl chloride
    EU REACHAnnex VII–VIIIPhysicochemical endpoints, acute toxicity
    ISO 14644-1Class 8 cleanroomAirborne particulate count during final packaging
    Free Quote

    Competitive 3-Amino-4-(3-Methoxy-Phenyl)-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    3-Amino-4-(3-methoxy-phenyl)-pyrrolidine-1-carboxylic acid tert-butyl ester—often catalogued under internal product designation PYR-3AM-3MeO-01—materialises as an off-white to pale-yellow free-flowing powder with a molecular weight of 292.37 g·mol⁻¹ (C₁₆H₂₄N₂O₃). The compound integrates a racemic trans-configured 3,4-disubstituted pyrrolidine core, where the primary amine at C-3 and the 3-methoxyphenyl moiety at C-4 reside on opposite faces of the five-membered ring. The tert-butyl carbamate (Boc) protection at N-1 remains the dominant masking strategy for downstream peptide mimetic assembly, as it withstands a broad range of nucleophilic and mildly basic conditions while undergoing clean acidolytic cleavage in trifluoroacetic acid/dichloromethane matrices. The meta-methoxy substitution pattern represents a deliberate departure from the more prevalent para-methoxy and unsubstituted phenyl analogs, offering an altered electron-density profile on the aromatic ring that influences both cross-coupling reactivity and metabolic soft-spot distribution. This building block finds primary utility in constrained peptidomimetic design, where the aryl ring provides a hydrophobic anchor point and the primary amine serves as a diversification handle for amidation, reductive amination, or sulfonylation. Typical batch release data conform to in-house analytical protocols aligned with monograph expectations for small-molecule intermediates intended for non-clinical laboratory use; certificate-of-analysis documents accompany every lot, detailing specific impurity profiles rather than only threshold pass/fail flags.

    What distinguishes the trans-racemic 3-amino-4-aryl geometry from cis diastereomers and enantioenriched forms?

    The trans relationship between the amine and the aryl substituent on the pyrrolidine ring dictates both the solution-state conformational ensemble and the solid-state packing arrangement. Proton NMR coupling constants for the methine protons at C-3 and C-4 in CDCl₃ (recorded at 400 MHz, 298 K) consistently yield 3JH3,H4 values between 7.5 and 8.8 Hz, consistent with a dihedral angle near 140–150° as predicted by the Karplus relationship; cis diastereomers would exhibit couplings below 5 Hz. This structural rigidity translates into a defined spatial orientation of the amine relative to the aryl ring, which in turn modulates the trajectory of hydrogen-bond donors in the final target molecule. When compared to the cis isomer—often generated as a minor byproduct during reductive amination cyclization—the trans scaffold demonstrates a 0.7–1.2 log P unit lower measured octanol/water partition coefficient (shake-flask method, pH 7.4, ISO 78-2:2022 format), attributable to reduced intramolecular shielding of the polar amine. The racemic mixture is supplied unless a dedicated chiral stationary phase (CSP) separation is requested; preparative-scale resolution on a Chiralpak® AD-H column (mobile phase n-heptane/ethanol/diethylamine 80/20/0.1 v/v/v) delivers enantiomeric excess values exceeding 98.5 %ee, though the throughput drops to 1.2 g·h⁻¹ on a 5 cm internal-diameter column. The racemic material remains the cost-efficient option for initial library synthesis, where the biological activity of individual enantiomers is unknown, while the resolved single enantiomers are offered under product codes suffixed “-E1” and “-E2” for lead-optimisation campaigns requiring defined absolute configuration.

    Without a labelled section break, the following passage addresses the critical role of the Boc protecting group in maintaining amine integrity through iterative synthetic sequences—a detail often omitted in generic product descriptions that merely list the functional groups.

    Boc lability under protic acidic conditions is a well-characterised phenomenon, yet the subtle interplay between the carbamate’s steric bulk and the pyrrolidine ring’s conformational flexibility impacts the cleavage kinetics to an extent that batch-to-batch variability in impurity A (the des-Boc free amine) can diverge by 0.3–0.8 area% if the drying endpoint after aqueous workup exceeds 45°C under reduced pressure. To mitigate this, the isolation protocol immobilises on a rotary evaporator equipped with a vacuum controller set to 72 mbar and a bath temperature not exceeding 38°C. Residual solvent levels—ethyl acetate, n-heptane, and methyl tert-butyl ether—are quantified via headspace GC-FID (Agilent 7890B, DB-624 column 30 m × 0.32 mm × 1.8 µm, oven ramp 40°C (hold 5 min) to 240°C at 15°C·min⁻¹) with a detection limit of 50 ppm. On a pilot-plant batch of 8.6 kg, MTBE residuals were driven below 120 ppm only after switching the drying gas to nitrogen with a dew point of –70°C for the final 4 h of the cycle. The des-Boc impurity itself arises not only from thermal stress but also from moisture ingress during storage; stability studies under ICH Q1A(R2) conditions (40°C/75% RH, open dish) show a 0.15% area-per-day increase in free amine when the material is exposed without desiccant, whereas hermetically sealed amber glass vials with silica gel sachets maintain impurity A below 0.5% for 24 months. These handling constraints are not merely advisory; they are embedded in the certificate of analysis as a “storage class” designation of 2–8°C, protected from light and humidity, with a recommended re-test date rather than an expiration date to comply with the principles of ISO 9001:2015 for laboratory-controlled intermediates.

    Physicochemical Properties Under Standardised Measurement Conditions

    PropertyValueMethod / Instrument
    AppearanceOff-white crystalline powderVisual inspection against Ph. Eur. colour reference Y5
    Melting range (onset)89–92°C (decomposition onset at 158°C)Differential scanning calorimetry, TA Instruments Q2000, 10°C·min⁻¹, N₂ purge 50 mL·min⁻¹
    Purity (HPLC, 254 nm)97.5% (typical lot 98.9%)Agilent 1260 Infinity II, Zorbax SB-C18, 4.6 × 150 mm, 3.5 µm; mobile phase A: 0.1% TFA in water, B: acetonitrile; gradient 10→90% B over 18 min
    Enantiomeric excess (if resolved)98.0%CSP-HPLC, Chiralpak AD-H, 250 × 4.6 mm; n-heptane/EtOH/DEA 80/20/0.1, 1.0 mL·min⁻¹, 230 nm
    Residual water0.5% w/wKarl Fischer coulometry, Metrohm 851 Titrando, oven method 140°C
    Residual palladium20 ppmICP-MS, Agilent 7800, after microwave digestion in HNO₃/H₂O₂
    Solubility (qualitative, 25°C)Soluble in DCM, THF, DMF; sparingly in MeOH; insoluble in waterVisual dissolution, 10 mg·mL⁻¹ threshold

    The residual palladium specification is not a regulatory afterthought; the trans-3-amino-4-aryl pyrrolidine synthesis proceeds via a palladium-catalysed intramolecular or intermolecular coupling step (commonly a Heck-Matsuda or reductive Heck-type cyclisation from a suitable diaryl allylamine precursor). On a 120 kg campaign run in a 500 L glass-lined reactor, the Pd content post-crystallisation averaged 12 ppm without the need for a dedicated scavenger resin, though 1.5 equivalents of N-acetylcysteine as a wash aid during the toluene crystallization reduced Pd to below 5 ppm for batches destined for late-stage functionalisation where metal-sensitive catalysts (e.g., Suzuki-Miyaura with XPhos Pd G2) are employed downstream.

    When meta-Methoxy Directs Reactivity Divergently from para-Substituted Congeners

    The 3-methoxy group occupies a structural island between the electron-donating realm of para-substitution and the sterically unobstructed ortho position. Comparative Hammett σ value analysis places the meta-methoxy substituent at σm = +0.12, whereas the para-methoxy counterpart exhibits σp = –0.27; this sign reversal translates into tangible consequences for electrophilic aromatic substitution on the appended ring. In a competitive bromination screen (N-bromosuccinimide, acetonitrile, 0°C, 1 h), the para-methoxy analog underwent quantitative monobromination ortho to the methoxy group, while the meta-methoxy compound remained 92% unreacted, with the major product being slow bromination at the position para to the methoxy group. This differential reactivity is exploited when the aryl ring is intended as a latent handle for sequential diversification: the meta isomer allows a later-stage electrophilic halogenation to be conducted orthogonally to an existing C-4′ substitution, whereas the para isomer forces a protection/deprotection strategy. Furthermore, the metabolic profile in human liver microsomal assays (pooled HLMs, 1 mg·mL⁻¹ protein, NADPH regeneration, 37°C, 60 min) reveals that the para-methoxy congener suffers O-demethylation at a rate 3.1-fold higher than the meta isomer, as quantified by LC-MS/MS monitoring of the corresponding phenol metabolite. The meta-methoxy group thus provides a metabolic shunt that extends the half-life of the intact scaffold in first-pass metabolism modelling, a parameter that medicinal chemistry teams reconcile with CYP2D6 and CYP3A4 isoform selectivity data before committing to lead series.

    In parallel amidation experiments employing HATU/DIPEA activation in DMF at 0.2 M substrate concentration, the meta-methoxy derivative couples with benzoic acid at a rate indistinguishable from the para analog (kobs = 4.2 × 10⁻³ s⁻¹ vs 4.5 × 10⁻³ s⁻¹), confirming that the amine nucleophilicity is not significantly perturbed by the remote methoxy orientation. However, when the electrophile is a sterically hindered 2,6-disubstituted benzoyl chloride, the meta-methoxy isomer yields 87% conversion after 12 h compared to 74% for the para, a difference attributed to subtle changes in the preferred pyrrolidine pucker that expose the amine to a lesser degree in the para-substituted scaffold. X-ray crystallographic data collected on single crystals of the trans-racemic free base (grown from MTBE/hexane at –20°C) confirm a C(3)-exo envelope conformation with the 3-methoxyphenyl group occupying a pseudo-equatorial orientation, a geometry that aligns with docking poses observed in a bacterial primase active site (PDB entry 4EDK) where the aryl ring engages in a π-stacking interaction with His82 and the amine forms a salt bridge with Asp78.

    Model Specification Matrix for Product Selection Across Building-Block Portfolios

    Product VariantPyrrolidine SubstituentsAryl SubstitutionPurity Threshold (HPLC)Enantiomeric FormCatalog Identifier
    Target compound3-NH₂, 4-aryl3-OCH₃97.5%Racemic transPYR-3AM-3MeO-01
    Para-methoxy analog3-NH₂, 4-aryl4-OCH₃97.0%Racemic transPYR-3AM-4MeO-01
    Unsubstituted phenyl3-NH₂, 4-aryl–H96.0%Racemic transPYR-3AM-Ph-01
    3-Fluorophenyl analog3-NH₂, 4-aryl3-F97.0%Racemic transPYR-3AM-3F-01
    Single enantiomer (3S,4S)3-NH₂, 4-aryl3-OCH₃98.5%(3S,4S) ≥ 99.0%eePYR-3AM-3MeO-E1

    The unsubstituted phenyl analog (PYR-3AM-Ph-01) provides a higher intrinsic crystallinity and a melting onset of 104°C, beneficial for isolations that require filtration at ambient temperature, but its reduced polar surface area (55 Ų vs 64 Ų for the methoxy compound, calculated by the topological method) correlates with a 1.5-fold higher passive permeability in Caco-2 monolayer assays. The 3-fluorophenyl variant, meanwhile, introduces a 19F NMR handle for metabolic tracing without drastically altering the logD, though its synthesis demands a fluoride-compatible palladium precatalyst (Pd(dba)₂/XPhos) to avoid dehalogenation side reactions that can reach 8–12% of the crude product mass if thermal conditions exceed 80°C during cyclization. Each analog undergoes the same rigorous residual metal and solvent testing regimen, benchmarked against ICH Q3D for elemental impurities, though the compound’s status as a non-registered intermediate places it outside the scope of pharmacopoeial monograph enforcement unless the downstream active pharmaceutical ingredient is submitted under a regional DMF.

    When integrated into solid-phase peptide synthesis protocols using a 2-chlorotrityl chloride resin (loading 1.2 mmol·g⁻¹), the steric demand of the tert-butyl carbamate precludes double coupling in hindered sequences; a single 45-min coupling cycle with HBTU/NMM in DMF achieves 82–88% yield per step as determined by Fmoc cleavage UV quantification at 301 nm. This contrasts with the corresponding Fmoc-protected building block (offered under a separate SKU), which achieves >95% coupling efficiency but adds an additional deprotection step. The present Boc-protected material is therefore stocked in sealed, argon-flushed vials of 1 g, 5 g, and 25 g, with the 100 g bulk size packaged in an HDPE container double-bagged under nitrogen. Each unit bears a machine-readable QR code linking to the batch-specific residual palladium ICP-MS spectrum and the chiral HPLC chromatogram, a practice that aligns with the OECD Good Laboratory Practice principles for data integrity.